Spironolactone, not furosemide, improved insulin resistance in patients with chronic heart failure

International Journal of Cardiology

Volumn 171, Issue 3, 2014, Pages 398-403

  Ogino, Kazuhide ^a   Kinugasa, Yoshiharu ^b   Kato, Masahiko ^b   Yamamoto, Kazuhiro ^b   Hisatome, Ichiro ^c   Anker, Stefan D ^d   Doehner, Wolfram ^d  

^a TOTTORI UNIVERSITY HOSPITAL   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

^c TOTTORI UNIVERSITY   (Japan)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Aldosterone; Diabetes; Heart failure; Inflammatory cytokine; Insulin resistance; Matrix metalloproteinase

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; FUROSEMIDE; GELATINASE A; GELATINASE B; GLUCOSE; INSULIN; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; SPIRONOLACTONE; TUMOR NECROSIS FACTOR ALPHA;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ALDOSTERONE; DIABETES; HEART FAILURE; INFLAMMATORY CYTOKINE; INSULIN RESISTANCE; MATRIX METALLOPROTEINASE;

AGED; BLOOD GLUCOSE; CHRONIC DISEASE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FUROSEMIDE; HEART FAILURE; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; SPIRONOLACTONE;

EID: 84893687879     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.12.039     Document Type: Article

References (36)

1. J.W. Swan, S.D. Anker, and C. Walton et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure J Am Coll Cardiol 30 1997 527 532
2. E. Ingelsson, J. Sundstrom, J. Arnlov, B. Zethelius, and L. Lind Insulin resistance and risk of congestive heart failure JAMA 294 2005 334 341
3. W. Doehner, M. Rauchhaus, and P. Ponikowski et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure J Am Coll Cardiol 46 2005 1019 1026
4. M.A. AlZadjali, V. Godfrey, and F. Khan et al. Insulin resistance is highly prevalent and is associated with reduced exercise tolerance in nondiabetic patients with heart failure J Am Coll Cardiol 53 2009 747 753
5. K. Matsushita, S. Blecker, and A. Pazin-Filho et al. The association of hemoglobin a1c with incident heart failure among people without diabetes: the atherosclerosis risk in communities study Diabetes 59 2010 2020 2026
6. B. Pitt, F. Zannad, and W.J. Remme et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators N Engl J Med 341 1999 709 717
7. B. Pitt, G. Williams, and W. Remme et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study Cardiovasc Drugs Ther 15 2001 79 87
8. F. Zannad, J.J. McMurray, and H. Krum et al. Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 2011 11 21
9. T. Wada, S. Ohshima, E. Fujisawa, D. Koya, H. Tsuneki, and T. Sasaoka Aldosterone inhibits insulin-induced glucose uptake by degradation of insulin receptor substrate (IRS) 1 and IRS2 via a reactive oxygen species-mediated pathway in 3T3-L1 adipocytes Endocrinology 150 2009 1662 1669
10. T. Wada, H. Kenmochi, and Y. Miyashita et al. Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet Endocrinology 151 2010 2040 2049
11. C. Catena, R. Lapenna, and S. Baroselli et al. Insulin sensitivity in patients with primary aldosteronism: a follow-up study J Clin Endocrinol Metab 91 2006 3457 3463
12. M.B. Murphy, P.J. Lewis, E. Kohner, B. Schumer, and C.T. Dollery Glucose intolerance in hypertensive patients treated with diuretics; a fourteen-year follow-up Lancet 2 1982 1293 1295
13. J.E. Carlsen, L. Kober, C. Torp-Pedersen, and P. Johansen Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects BMJ 300 1990 975 978
14. D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, and R.C. Turner Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 1985 412 419
15. N.B. Schiller, P.M. Shah, and M. Crawford et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms J Am Soc Echocardiogr 2 1989 358 367
16. M. Hills, and P. Armitage The two-period cross-over clinical trial Br J Clin Pharmacol 8 1979 7 20
17. F. Fallo, F. Veglio, and C. Bertello et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism J Clin Endocrinol Metab 91 2006 454 459
18. K. Shimamoto, M. Shiiki, and T. Ise et al. Does insulin resistance participate in an impaired glucose tolerance in primary aldosteronism? J Hum Hypertens 8 1994 755 759
19. G. Giacchetti, V. Ronconi, and F. Turchi et al. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study J Hypertens 25 2007 177 186
20. H. Hitomi, H. Kiyomoto, and A. Nishiyama et al. Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells Hypertension 50 2007 750 755
21. M. Yamaji, T. Tsutamoto, and C. Kawahara et al. Effect of eplerenone versus spironolactone on cortisol and hemoglobin A(1)(c) levels in patients with chronic heart failure Am Heart J 160 2010 915 921
22. H. Kanda, S. Tateya, and Y. Tamori et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity J Clin Invest 116 2006 1494 1505
23. H. Sell, D. Dietze-Schroeder, U. Kaiser, and J. Eckel Monocyte chemotactic protein-1 is a potential player in the negative cross-talk between adipose tissue and skeletal muscle Endocrinology 147 2006 2458 2467
24. H. Inoue, W. Ogawa, and A. Asakawa et al. Role of hepatic STAT3 in brain-insulin action on hepatic glucose production Cell Metab 3 2006 267 275
25. M. Rauchhaus, W. Doehner, and D.P. Francis et al. Plasma cytokine parameters and mortality in patients with chronic heart failure Circulation 102 2000 3060 3067
26. M. Valgimigli, C. Ceconi, and P. Malagutti et al. Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) Study Circulation 111 2005 863 870
27. P. Guo, A. Nishiyama, and M. Rahman et al. Contribution of reactive oxygen species to the pathogenesis of left ventricular failure in Dahl salt-sensitive hypertensive rats: effects of angiotensin II blockade J Hypertens 24 2006 1097 1104
28. P. Dandona, V. Kumar, and A. Aljada et al. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action J Clin Endocrinol Metab 88 2003 4496 4501
29. K.K. Koh, J.Y. Ahn, and S.H. Han et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients J Am Coll Cardiol 42 2003 905 910
30. T. Tsutamoto, A. Wada, and K. Maeda et al. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure J Am Coll Cardiol 35 2000 714 721
31. J. Suzuki, M. Iwai, and M. Mogi et al. Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation Arterioscler Thromb Vasc Biol 26 2006 917 921
32. C. Guo, V. Ricchiuti, and B.Q. Lian et al. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines Circulation 117 2008 2253 2261
33. G.M. Kuster, E. Kotlyar, and M.K. Rude et al. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload Circulation 111 2005 420 427
34. N.J. Brown Aldosterone and vascular inflammation Hypertension 51 2008 161 167
35. K.T. Weber From inflammation to fibrosis: a stiff stretch of highway Hypertension 43 2004 716 719
36. F.A. DeLano, and G.W. Schmid-Schonbein Proteinase activity and receptor cleavage: mechanism for insulin resistance in the spontaneously hypertensive rat Hypertension 52 2008 415 423 Technology